No Data
No Data
Zymeworks Begins Trial for Promising Cancer Therapy
ZymeWorks Has Dosed The First Patient In The First-In-Human Phase 1 Trial To Evaluate The Safety And Tolerability Of The Investigational Therapy ZW171 For Advanced Or Metastatic Ovarian Cancer, NSCLC, And Other MSLN-expressing Cancers
Express News | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks Announces Board Changes With New Appointments
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Maintaining Neutral: Hold Rating on Zymeworks Amidst Preclinical Progress and Upcoming Catalysts